Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Drug PIC

MSD’s KEYTRUDA Wins NMPA Approval for Perioperative Treatment of Resectable Locally Advanced HNSCC in China

Fineline Cube Sep 4, 2026
Company Deals PIC

Typewriter Therapeutics Raises USD 56 Million Series A to Advance TPRT RNA Gene Insertion Platform for In Vivo CAR-T and Liver Diseases

Fineline Cube Sep 4, 2026
Company Deals Drug PIC

Takeda and Belief BioMed End Xinjiuning Commercialization Partnership; Belief BioMed to Advance Gene Therapy Independently

Fineline Cube Sep 4, 2026
Company Deals Drug PIC

Keymed Biosciences Grants Aeira Exclusive Rights to Stapokibart Across 18 Southeast and Central Asia Markets, Securing High Double‑Digit Royalties

Fineline Cube Sep 3, 2026
Company Deals PIC

Medtronic Invests USD 700 Million in Cornerstone Robotics, Wins Distribution Rights for Sentire Endoscopic Surgical Robot Outside the U.S.

Fineline Cube Sep 3, 2026
Company Drug PIC

MSD’s KEYTRUDA Wins NMPA Approval for Perioperative Treatment of Resectable Locally Advanced HNSCC in China

Fineline Cube Sep 4, 2026
Company Drug PIC

MSD’s KEYTRUDA Wins NMPA Approval for Perioperative Treatment of Resectable Locally Advanced HNSCC in China

Fineline Cube Sep 4, 2026
Policy / Regulatory

China’s 2026 NHSA Drug Negotiations Open Sept 5 with Parallel Commercial Insurance Innovative Drug Catalog Talks

Fineline Cube Sep 4, 2026
Company Deals

Organon Acquires U.S. Rights to TOFIDENCE from Biogen

Fineline Cube Apr 2, 2025

Organon (NYSE: OGN) announced today that it has acquired regulatory and commercial rights in the...

Company Drug

Zhifei Bio’s Trivalent Influenza Vaccine Approved for Clinical Trials in China

Fineline Cube Apr 2, 2025

Zhifei Biological (SHE: 300122) announced on April 1, 2025, that its subsidiary Zhifei Longcom has...

Company Deals

ChemPartner Plans Share Issuance to Raise Up to 316.3 Million Yuan

Fineline Cube Apr 2, 2025

On April 2, 2025, ChemPartner Pharmatech (SHE: 300149) announced plans to issue shares to a...

Company Deals Medical Device

Peijia Medical and DSM-Firmenich Collaborate on Polymer Heart Valve Innovation

Fineline Cube Apr 2, 2025

Peijia Medical Technology (Suzhou) Co., Ltd. today held a strategic innovation cooperation signing ceremony and...

Company Drug

Henlius and Organon’s HLX11 Biosimilar Clears EMA Validation Hurdle

Fineline Cube Apr 2, 2025

Shanghai Henlius Biotech, Inc. (HKG: 2696) and Organon (NYSE: OGN) announced that the European Medicines...

Company Drug

Huadong Medicine’s Semaglutide Injection Accepted for Review by China’s NMPA

Fineline Cube Apr 2, 2025

China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that the National Medical Products Administration (NMPA)...

Company Deals

Medtronic Partners with Methinks AI to Enhance Stroke Care in Emerging Markets

Fineline Cube Apr 2, 2025

Medtronic announced a strategic partnership with Methinks AI, a leading provider of AI-driven radiological triage...

Company Drug

Hengrui Pharmaceuticals Secures Clinical Trial Approval for HRS-9813 in IPF

Fineline Cube Apr 2, 2025

Hengrui Pharmaceuticals (SHA: 600276) announced on April 1, 2025, that its HRS-9813 capsule has received...

Company Medical Device

Sino Medical Sciences Secures Malaysian Approval for Coronary Balloon Catheter

Fineline Cube Apr 1, 2025

China-based Sino Medical Sciences Technology Inc. (SHA: 688108) has announced receiving marketing approval in Malaysia...

Company Drug

Luye Pharma’s Weekly Rivastigmine Patch Approved in Japan for Alzheimer’s

Fineline Cube Apr 1, 2025

China-based Luye Pharma Group (HKG: 2186) announced that it has received marketing approval from Japan’s...

Company Drug

BeiGene’s Tevimbra Recommended for EU Approval in Small Cell Lung Cancer

Fineline Cube Apr 1, 2025

BeiGene, Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235), the China-based oncology specialist proposing to rename...

Company Drug

Otsuka Files FDA Application for Sibeprenlimab in IgAN Treatment

Fineline Cube Apr 1, 2025

Japan-based Otsuka Pharmaceutical Co., Ltd. announced the filing of a Biologics License Application (BLA) with...

Company

Basecare Medical Reports 44% Revenue Growth in 2024 IVF Sector

Fineline Cube Apr 1, 2025

China-based IVF specialist Suzhou Basecare Medical Co., Ltd (HKG: 2170) has released its 2024 performance...

Company Drug

UCB’s Rystiggo Approved in China for Generalized Myasthenia Gravis

Fineline Cube Apr 1, 2025

Belgium-based biopharma UCB (EBR: UCB) announced that it has received marketing approval from China‘’s National...

Deals Hospital

Renji Hospital Partners with Raffles Medical Group to Boost Shanghai’s Medical Tourism

Fineline Cube Apr 1, 2025

Renji Hospital, a comprehensive Class 3A hospital established in 1844 in Shanghai, has partnered with...

Company Drug

AstraZeneca and Daiichi Sankyo Initiate DESTINY-Gastric05 Study for Enhertu in Metastatic Gastric Cancer

Fineline Cube Apr 1, 2025

Partners AstraZeneca (NASDAQ: AZN) and Daiichi Sankyo (TYO: 4568) announced the first patient dosing in...

Medical Device Policy / Regulatory

China Proposes New Measures to Optimize High-End Medical Device Regulation

Fineline Cube Apr 1, 2025

The National Medical Products Administration (NMPA) has released the “Measures for Optimizing Full Lifecycle Supervision...

Company Deals

GE Healthcare Takes Full Ownership of Japan’s Nihon Medi-Physics

Fineline Cube Apr 1, 2025

US medical device and life sciences giant GE Healthcare Technologies Inc., (NASDAQ: GEHC) announced that...

Company Drug

Hengrui Pharmaceuticals’ Ivarmacitinib Approved for Rheumatoid Arthritis in China

Fineline Cube Apr 1, 2025

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received additional indication approval...

Company Deals

Chinese Firms Nanjing F&S and Hunan Huize Form Alliance for Full-Process Pharma Services

Fineline Cube Apr 1, 2025

Chinese companies Nanjing F&S Pharmatech Co., Ltd and Hunan Huize Biopharmaceutical Technology Co., Ltd, a...

Posts pagination

1 … 235 236 237 … 716

Recent updates

  • MSD’s KEYTRUDA Wins NMPA Approval for Perioperative Treatment of Resectable Locally Advanced HNSCC in China
  • China’s 2026 NHSA Drug Negotiations Open Sept 5 with Parallel Commercial Insurance Innovative Drug Catalog Talks
  • Trinomab’s Retavibart Wins NMPA Priority Approval as RSV Prevention Monoclonal Antibody Xinduotuo
  • Xuanzhu Biopharmaceutical Signs Thailand Commercial Agreement with Innobic and ZaoAn for Bireociclib
  • Betta’s Ensartinib Wins NMPA Approval for Third Indication as Adjuvant Therapy in ALK-Positive NSCLC
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Drug PIC

MSD’s KEYTRUDA Wins NMPA Approval for Perioperative Treatment of Resectable Locally Advanced HNSCC in China

Policy / Regulatory

China’s 2026 NHSA Drug Negotiations Open Sept 5 with Parallel Commercial Insurance Innovative Drug Catalog Talks

Company Drug

Trinomab’s Retavibart Wins NMPA Priority Approval as RSV Prevention Monoclonal Antibody Xinduotuo

Company Deals

Xuanzhu Biopharmaceutical Signs Thailand Commercial Agreement with Innobic and ZaoAn for Bireociclib

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2026 | Fineline Information & Technology | BlogData by Themeansar.